Impact of Baseline Clinicopathologic and Genomic Features on Outcomes to KRAS G12C Inhibitors in Patients with NSCLC

被引：0
|
作者：
Lamberti, G. [1 ]
Ricciuti, B. [1 ]
Alessi, J. V. [1 ]
Barrichello, A. P. C. [1 ]
Pecci, F. [1 ]
Vaz, V. R. [1 ]
Sholl, L. M. [2 ]
Awad, M. M. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Brigham & Womens Hosp, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
KRAS G12C; KRAS inhibitors; Predictive factors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA02.09
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 50 条
  • [21] KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer
    Xiao, Annie
    Fakih, Marwan
    CLINICAL COLORECTAL CANCER, 2024, 23 (03) : 199 - 206
  • [22] Overcoming resistance to KRAS G12C inhibitors in lung cancer
    Ambrogio, Chiara
    CANCER SCIENCE, 2023, 114 : 987 - 987
  • [23] Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors
    Arbour, Kathryn C.
    Lito, Piro
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (23) : 2609 - +
  • [24] Breaking barriers: the latest insights into KRAS G12C inhibitors
    Attieh, Fouad
    Kourie, Hampig Raphael
    FUTURE ONCOLOGY, 2024, 20 (35) : 2685 - 2688
  • [25] Let's bring back old drugs to conquer resistance to KRAS G12C inhibitors in NSCLC
    Jain, A.
    Shivamallu, C.
    Prasad, A.
    Dharmashekhar, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S1557 - S1557
  • [26] Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C
    Zeng, Mei
    Lu, Jia
    Li, Lianbo
    Feru, Frederic
    Quan, Chunshan
    Gero, Thomas W.
    Ficarro, Scott B.
    Xiong, Yuan
    Ambrogio, Chiara
    Paranal, Raymond M.
    Catalano, Marco
    Shao, Jay
    Wong, Kwok-Kin
    Marto, Jarrod A.
    Fischer, Eric S.
    Janne, Pasi A.
    Scott, David A.
    Westover, Kenneth D.
    Gray, Nathanael S.
    CELL CHEMICAL BIOLOGY, 2017, 24 (08): : 1005 - +
  • [27] KRAS G12C Inhibitors: New Drugs, A New Hope
    Singhal, Surbhi
    Schokrpur, Shiruyeh
    Gandara, David
    Riess, Jonathan W.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (12) : 1594 - 1598
  • [28] Characterizing the clinico-genomic landscape and outcomes of KRAS G12C mutated pancreas cancer
    Keane, F.
    Park, W.
    Varghese, A.
    Balogun, F.
    Yu, K.
    El Dika, I.
    Khalil, D.
    Kelsen, D. P.
    Reidy-Lagunes, D.
    Ku, G. Y.
    Raj, N.
    Chou, J. F.
    Capanu, M.
    Schultz, N.
    Yaeger, R.
    O'Reilly, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1140 - S1140
  • [29] Targeting the KRAS G12C Mutation in NSCLC For a early, deep and sustained Remission
    Fessler, Beate
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (04) : 230 - 230
  • [30] KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
    Lim, Tony Kiat Hon
    Skoulidis, Ferdinandos
    Kerr, Keith M.
    Ahn, Myung-Ju
    Kapp, Joshua R.
    Soares, Fernando A.
    Yatabe, Yasushi
    LUNG CANCER, 2023, 184
12345